Loading…

Determinants for drug prescribing to children below the minimum licensed age

In the light of the undesired effects that unlicensed and off-label drug use might have, it is necessary to study the determinants affecting the prescribing of such drugs. Prescription of drugs to children younger than the minimum licensed age may carry the highest risk of adverse reactions. To obta...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical pharmacology 2003-02, Vol.58 (10), p.701-705
Main Authors: W.'T JONG, Geert, ELAND, Ingo A, STURKENBOOM, Miriam C. J. M, VAN DEN ANKER, John N, STRICKER, Bruno H. C
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c354t-b5e432e411230e8752404d6cab54e78209b2e2983b92c9a20df5c438a5b6efcc3
cites cdi_FETCH-LOGICAL-c354t-b5e432e411230e8752404d6cab54e78209b2e2983b92c9a20df5c438a5b6efcc3
container_end_page 705
container_issue 10
container_start_page 701
container_title European journal of clinical pharmacology
container_volume 58
creator W.'T JONG, Geert
ELAND, Ingo A
STURKENBOOM, Miriam C. J. M
VAN DEN ANKER, John N
STRICKER, Bruno H. C
description In the light of the undesired effects that unlicensed and off-label drug use might have, it is necessary to study the determinants affecting the prescribing of such drugs. Prescription of drugs to children younger than the minimum licensed age may carry the highest risk of adverse reactions. To obtain insight into the factors that affect prescription of drugs to children below the minimum licensed age, we conducted a population-based case-control study. The case-control study was nested in a cohort of 13,426 children aged 0-16 years, who were registered in the Integrated Primary Care Information (IPCI) project, a longitudinal observational general practitioners' database in the Netherlands. "Cases" were children who received a drug prescription for which they were below the minimum licensed age. To each case we matched up to four controls based on GP practice and patient age. As potential risk factors we evaluated the use of health care resources, and acute and chronic morbidity. We identified 447 cases who were matched to 1355 controls. The cases consulted their GPs significantly more often during the preceding half year, had more drug prescriptions, and had more specialist referrals than the controls. Respiratory diseases were the most important determinants for the prescription of drugs to children below the minimum licensed age. In adolescents, migraine and other headaches were the most important reasons. This study showed that children suffering from respiratory disease or migraine have the highest risk of receiving a drug prescription for which the patient is below the minimum licensed age. Regulatory authorities and the pharmaceutical industry should be stimulated to improve the evaluation of drug efficacy and safety in children.
doi_str_mv 10.1007/s00228-002-0554-2
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73067256</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>819115411</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-b5e432e411230e8752404d6cab54e78209b2e2983b92c9a20df5c438a5b6efcc3</originalsourceid><addsrcrecordid>eNpdkEtLxDAUhYMoOj5-gBsJgu6qN-92Kb5hwI2uQ5rejpE-xqRF_PdGZkBwc-7mO4fLR8gpgysGYK4TAOdlkbMApWTBd8iCScELBpLtkgWAYIWuDByQw5Q-AJiqQOyTA8Y1AyPLBVne4YSxD4MbpkTbMdImziu6jph8DHUYVnQaqX8PXRNxoDV24xed3pHmSujnnnbB45CwoW6Fx2SvdV3Ck-09Im8P96-3T8Xy5fH59mZZeKHkVNQK85MoGeMCsDSKS5CN9q5WEk3Joao58qoUdcV95Tg0rfJSlE7VGlvvxRG53Oyu4_g5Y5psH5LHrnMDjnOyRoA2XOkMnv8DP8Y5Dvk3y5mURmuuMsQ2kI9jShFbu46hd_HbMrC_nu3Gs81pfz1bnjtn2-G57rH5a2zFZuBiC7jkXddGN_iQ_jipQRipxA-GfoQ6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>214476625</pqid></control><display><type>article</type><title>Determinants for drug prescribing to children below the minimum licensed age</title><source>Springer Nature:Jisc Collections:Springer Nature Read and Publish 2023-2025: Springer Reading List</source><creator>W.'T JONG, Geert ; ELAND, Ingo A ; STURKENBOOM, Miriam C. J. M ; VAN DEN ANKER, John N ; STRICKER, Bruno H. C</creator><creatorcontrib>W.'T JONG, Geert ; ELAND, Ingo A ; STURKENBOOM, Miriam C. J. M ; VAN DEN ANKER, John N ; STRICKER, Bruno H. C</creatorcontrib><description>In the light of the undesired effects that unlicensed and off-label drug use might have, it is necessary to study the determinants affecting the prescribing of such drugs. Prescription of drugs to children younger than the minimum licensed age may carry the highest risk of adverse reactions. To obtain insight into the factors that affect prescription of drugs to children below the minimum licensed age, we conducted a population-based case-control study. The case-control study was nested in a cohort of 13,426 children aged 0-16 years, who were registered in the Integrated Primary Care Information (IPCI) project, a longitudinal observational general practitioners' database in the Netherlands. "Cases" were children who received a drug prescription for which they were below the minimum licensed age. To each case we matched up to four controls based on GP practice and patient age. As potential risk factors we evaluated the use of health care resources, and acute and chronic morbidity. We identified 447 cases who were matched to 1355 controls. The cases consulted their GPs significantly more often during the preceding half year, had more drug prescriptions, and had more specialist referrals than the controls. Respiratory diseases were the most important determinants for the prescription of drugs to children below the minimum licensed age. In adolescents, migraine and other headaches were the most important reasons. This study showed that children suffering from respiratory disease or migraine have the highest risk of receiving a drug prescription for which the patient is below the minimum licensed age. Regulatory authorities and the pharmaceutical industry should be stimulated to improve the evaluation of drug efficacy and safety in children.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/s00228-002-0554-2</identifier><identifier>PMID: 12610748</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Adolescent ; Age Factors ; Biological and medical sciences ; Case-Control Studies ; Child ; Child, Preschool ; Drug Labeling - legislation &amp; jurisprudence ; Drug Prescriptions - statistics &amp; numerical data ; Drug Utilization ; Female ; General pharmacology ; Humans ; Infant ; Infant, Newborn ; Legislation, Drug ; Male ; Medical sciences ; Miscellaneous ; Pharmaceutical Preparations - administration &amp; dosage ; Pharmacology. Drug treatments ; Practice Patterns, Physicians' - trends ; Risk Factors</subject><ispartof>European journal of clinical pharmacology, 2003-02, Vol.58 (10), p.701-705</ispartof><rights>2003 INIST-CNRS</rights><rights>Springer-Verlag 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-b5e432e411230e8752404d6cab54e78209b2e2983b92c9a20df5c438a5b6efcc3</citedby><cites>FETCH-LOGICAL-c354t-b5e432e411230e8752404d6cab54e78209b2e2983b92c9a20df5c438a5b6efcc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14603745$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12610748$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>W.'T JONG, Geert</creatorcontrib><creatorcontrib>ELAND, Ingo A</creatorcontrib><creatorcontrib>STURKENBOOM, Miriam C. J. M</creatorcontrib><creatorcontrib>VAN DEN ANKER, John N</creatorcontrib><creatorcontrib>STRICKER, Bruno H. C</creatorcontrib><title>Determinants for drug prescribing to children below the minimum licensed age</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><description>In the light of the undesired effects that unlicensed and off-label drug use might have, it is necessary to study the determinants affecting the prescribing of such drugs. Prescription of drugs to children younger than the minimum licensed age may carry the highest risk of adverse reactions. To obtain insight into the factors that affect prescription of drugs to children below the minimum licensed age, we conducted a population-based case-control study. The case-control study was nested in a cohort of 13,426 children aged 0-16 years, who were registered in the Integrated Primary Care Information (IPCI) project, a longitudinal observational general practitioners' database in the Netherlands. "Cases" were children who received a drug prescription for which they were below the minimum licensed age. To each case we matched up to four controls based on GP practice and patient age. As potential risk factors we evaluated the use of health care resources, and acute and chronic morbidity. We identified 447 cases who were matched to 1355 controls. The cases consulted their GPs significantly more often during the preceding half year, had more drug prescriptions, and had more specialist referrals than the controls. Respiratory diseases were the most important determinants for the prescription of drugs to children below the minimum licensed age. In adolescents, migraine and other headaches were the most important reasons. This study showed that children suffering from respiratory disease or migraine have the highest risk of receiving a drug prescription for which the patient is below the minimum licensed age. Regulatory authorities and the pharmaceutical industry should be stimulated to improve the evaluation of drug efficacy and safety in children.</description><subject>Adolescent</subject><subject>Age Factors</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Drug Labeling - legislation &amp; jurisprudence</subject><subject>Drug Prescriptions - statistics &amp; numerical data</subject><subject>Drug Utilization</subject><subject>Female</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Legislation, Drug</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Pharmaceutical Preparations - administration &amp; dosage</subject><subject>Pharmacology. Drug treatments</subject><subject>Practice Patterns, Physicians' - trends</subject><subject>Risk Factors</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNpdkEtLxDAUhYMoOj5-gBsJgu6qN-92Kb5hwI2uQ5rejpE-xqRF_PdGZkBwc-7mO4fLR8gpgysGYK4TAOdlkbMApWTBd8iCScELBpLtkgWAYIWuDByQw5Q-AJiqQOyTA8Y1AyPLBVne4YSxD4MbpkTbMdImziu6jph8DHUYVnQaqX8PXRNxoDV24xed3pHmSujnnnbB45CwoW6Fx2SvdV3Ck-09Im8P96-3T8Xy5fH59mZZeKHkVNQK85MoGeMCsDSKS5CN9q5WEk3Joao58qoUdcV95Tg0rfJSlE7VGlvvxRG53Oyu4_g5Y5psH5LHrnMDjnOyRoA2XOkMnv8DP8Y5Dvk3y5mURmuuMsQ2kI9jShFbu46hd_HbMrC_nu3Gs81pfz1bnjtn2-G57rH5a2zFZuBiC7jkXddGN_iQ_jipQRipxA-GfoQ6</recordid><startdate>20030201</startdate><enddate>20030201</enddate><creator>W.'T JONG, Geert</creator><creator>ELAND, Ingo A</creator><creator>STURKENBOOM, Miriam C. J. M</creator><creator>VAN DEN ANKER, John N</creator><creator>STRICKER, Bruno H. C</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20030201</creationdate><title>Determinants for drug prescribing to children below the minimum licensed age</title><author>W.'T JONG, Geert ; ELAND, Ingo A ; STURKENBOOM, Miriam C. J. M ; VAN DEN ANKER, John N ; STRICKER, Bruno H. C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-b5e432e411230e8752404d6cab54e78209b2e2983b92c9a20df5c438a5b6efcc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adolescent</topic><topic>Age Factors</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Drug Labeling - legislation &amp; jurisprudence</topic><topic>Drug Prescriptions - statistics &amp; numerical data</topic><topic>Drug Utilization</topic><topic>Female</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Legislation, Drug</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Pharmaceutical Preparations - administration &amp; dosage</topic><topic>Pharmacology. Drug treatments</topic><topic>Practice Patterns, Physicians' - trends</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>W.'T JONG, Geert</creatorcontrib><creatorcontrib>ELAND, Ingo A</creatorcontrib><creatorcontrib>STURKENBOOM, Miriam C. J. M</creatorcontrib><creatorcontrib>VAN DEN ANKER, John N</creatorcontrib><creatorcontrib>STRICKER, Bruno H. C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>W.'T JONG, Geert</au><au>ELAND, Ingo A</au><au>STURKENBOOM, Miriam C. J. M</au><au>VAN DEN ANKER, John N</au><au>STRICKER, Bruno H. C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Determinants for drug prescribing to children below the minimum licensed age</atitle><jtitle>European journal of clinical pharmacology</jtitle><addtitle>Eur J Clin Pharmacol</addtitle><date>2003-02-01</date><risdate>2003</risdate><volume>58</volume><issue>10</issue><spage>701</spage><epage>705</epage><pages>701-705</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>In the light of the undesired effects that unlicensed and off-label drug use might have, it is necessary to study the determinants affecting the prescribing of such drugs. Prescription of drugs to children younger than the minimum licensed age may carry the highest risk of adverse reactions. To obtain insight into the factors that affect prescription of drugs to children below the minimum licensed age, we conducted a population-based case-control study. The case-control study was nested in a cohort of 13,426 children aged 0-16 years, who were registered in the Integrated Primary Care Information (IPCI) project, a longitudinal observational general practitioners' database in the Netherlands. "Cases" were children who received a drug prescription for which they were below the minimum licensed age. To each case we matched up to four controls based on GP practice and patient age. As potential risk factors we evaluated the use of health care resources, and acute and chronic morbidity. We identified 447 cases who were matched to 1355 controls. The cases consulted their GPs significantly more often during the preceding half year, had more drug prescriptions, and had more specialist referrals than the controls. Respiratory diseases were the most important determinants for the prescription of drugs to children below the minimum licensed age. In adolescents, migraine and other headaches were the most important reasons. This study showed that children suffering from respiratory disease or migraine have the highest risk of receiving a drug prescription for which the patient is below the minimum licensed age. Regulatory authorities and the pharmaceutical industry should be stimulated to improve the evaluation of drug efficacy and safety in children.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>12610748</pmid><doi>10.1007/s00228-002-0554-2</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0031-6970
ispartof European journal of clinical pharmacology, 2003-02, Vol.58 (10), p.701-705
issn 0031-6970
1432-1041
language eng
recordid cdi_proquest_miscellaneous_73067256
source Springer Nature:Jisc Collections:Springer Nature Read and Publish 2023-2025: Springer Reading List
subjects Adolescent
Age Factors
Biological and medical sciences
Case-Control Studies
Child
Child, Preschool
Drug Labeling - legislation & jurisprudence
Drug Prescriptions - statistics & numerical data
Drug Utilization
Female
General pharmacology
Humans
Infant
Infant, Newborn
Legislation, Drug
Male
Medical sciences
Miscellaneous
Pharmaceutical Preparations - administration & dosage
Pharmacology. Drug treatments
Practice Patterns, Physicians' - trends
Risk Factors
title Determinants for drug prescribing to children below the minimum licensed age
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T02%3A39%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Determinants%20for%20drug%20prescribing%20to%20children%20below%20the%20minimum%20licensed%20age&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=W.'T%20JONG,%20Geert&rft.date=2003-02-01&rft.volume=58&rft.issue=10&rft.spage=701&rft.epage=705&rft.pages=701-705&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/s00228-002-0554-2&rft_dat=%3Cproquest_cross%3E819115411%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c354t-b5e432e411230e8752404d6cab54e78209b2e2983b92c9a20df5c438a5b6efcc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=214476625&rft_id=info:pmid/12610748&rfr_iscdi=true